{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:39:46Z","timestamp":1768786786084,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council","award":["APP1008473"],"award-info":[{"award-number":["APP1008473"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.phrs.2015.07.023","type":"journal-article","created":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T15:15:17Z","timestamp":1437923717000},"page":"36-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPK\u03b1-SREBP-1 and PPAR\u03b1-dependent pathways"],"prefix":"10.1016","volume":"100","author":[{"given":"Xuemei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamei","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2015.07.023_bib0005","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.phrs.2015.07.023_bib0010","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","volume":"3","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2015.07.023_bib0015","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.euroneuro.2011.04.001","article-title":"Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies","volume":"21","author":"Zuddas","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ecl.2013.05.006","article-title":"Effects of antipsychotic medications on appetite, weight, and insulin resistance","volume":"42","author":"Deng","year":"2013","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.phrs.2015.07.023_bib0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"Correll","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.phrs.2015.07.023_bib0030","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/pds.1424","article-title":"Cardiovascular risks of atypical antipsychotic drug treatment","volume":"16","author":"Drici","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.phrs.2015.07.023_bib0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","article-title":"Which comes first: atypical antipsychotic treatment or cardiometabolic risk?","volume":"119","author":"Stahl","year":"2009","journal-title":"Acta Psychiatry Scand."},{"key":"10.1016\/j.phrs.2015.07.023_bib0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/JCP.0b013e318166c4f7","article-title":"Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions","volume":"28","author":"Birkenaes","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0045","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1289\/ehp.11342","article-title":"Perinatal exposure to bisphenol a alters early adipogenesis in the rat","volume":"117","author":"Somm","year":"2009","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.phrs.2015.07.023_bib0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145711001271","article-title":"Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats","volume":"15","author":"Skrede","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lfs.2015.01.033","article-title":"Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats","volume":"128","author":"Liu","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2015.07.023_bib0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2741\/3675","article-title":"Lipogenic effects of psychotropic drugs: focus on the SREBP system","volume":"16","author":"Fern\u00f8","year":"2011","journal-title":"Front. Biosci."},{"key":"10.1016\/j.phrs.2015.07.023_bib0065","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2010\/549101","article-title":"AMPK-dependent metabolic regulation by PPAR agonists","volume":"2010","author":"Lee","year":"2010","journal-title":"PPAR Res."},{"key":"10.1016\/j.phrs.2015.07.023_bib0070","doi-asserted-by":"crossref","first-page":"E624","DOI":"10.1152\/ajpendo.00502.2010","article-title":"Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism","volume":"300","author":"Oh","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2015.07.023_bib0075","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1194\/jlr.R025882","article-title":"AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases","volume":"53","author":"Srivastava","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2015.07.023_bib0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1113\/jphysiol.2006.108506","article-title":"Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders","volume":"574","author":"Viollet","year":"2006","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0085","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bbalip.2007.04.018","article-title":"Modulation of PPAR activity via phosphorylation","volume":"1771","author":"Burns","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2015.07.023_bib0090","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/jpet.113.207621","article-title":"Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs","volume":"347","author":"Schmidt","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.07.023_bib0095","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00210-010-0495-8","article-title":"Site-specific modulation of white adipose tissue lipid metabolism by oleoyl-estrone and\/or rosiglitazone in overweight rats","volume":"381","author":"Ferrer-Lorente","year":"2010","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0100","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/sj.ki.5002370","article-title":"Histamine ameliorates anti-glomerular basement membrane antibody-induced glomerulonephritis in rats","volume":"72","author":"Tanda","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2015.07.023_bib0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.psyneuen.2014.06.010","article-title":"Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways","volume":"48","author":"Lian","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2015.07.023_bib0110","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1210\/en.2014-1326","article-title":"Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats","volume":"155","author":"He","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2015.07.023_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2009.11.009","article-title":"The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?","volume":"34","author":"Deng","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2015.07.023_bib0120","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.07.023_bib0125","doi-asserted-by":"crossref","first-page":"e104160","DOI":"10.1371\/journal.pone.0104160","article-title":"Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment","volume":"9","author":"Lian","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2015.07.023_bib0130","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00213-012-2935-2","article-title":"Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination","volume":"226","author":"Poyurovsky","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.phrs.2015.07.023_bib0135","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1177\/0269881112449396","article-title":"Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model","volume":"26","author":"Deng","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004850-200503000-00007","article-title":"The effect of betahistine, a histamine H1 receptor agonist\/Hantagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients","volume":"20","author":"Poyurovsky","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pnpbp.2013.08.005","article-title":"Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density","volume":"47","author":"Lian","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2015.07.023_bib0150","unstructured":"FDA. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. http:\/\/wwwfdagov\/cder\/guidance\/indexhtm 2005."},{"key":"10.1016\/j.phrs.2015.07.023_bib0155","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2007","journal-title":"FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0160","first-page":"24","article-title":"Effects of betahistine and of its metabolites on vestibular sensory organs","volume":"21","author":"Botta","year":"2001","journal-title":"Acta Otorhinolaryngol. Italica: Organo Ufficiale della Societa Italiana di Otorinolaringologia e Chirurgia Cervico-Facciale"},{"key":"10.1016\/j.phrs.2015.07.023_bib0165","first-page":"701","article-title":"Betahistine inhibits food intake in rats","volume":"53","author":"Szelag","year":"2001","journal-title":"Pol. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0170","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cmet.2005.03.001","article-title":"LXRs regulate the balance between fat storage and oxidation","volume":"1","author":"Kalaany","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2015.07.023_bib0175","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jsbmb.2012.06.001","article-title":"Cholesterol metabolite, 5-cholesten-3beta-25-diol-3-sulfate, promotes hepatic proliferation in mice","volume":"132","author":"Zhang","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0180","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nprot.2013.055","article-title":"Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease","volume":"8","author":"Mehlem","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.phrs.2015.07.023_bib0185","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/BF01967334","article-title":"Inhibition by disodium cromoglycate of anaphylactic histamine secretion from rat peritoneal mast cells in the presence of phosphatidylserine","volume":"13","author":"Pearce","year":"1983","journal-title":"Agents Actions"},{"key":"10.1016\/j.phrs.2015.07.023_bib0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2202-7-69","article-title":"Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs","volume":"7","author":"Fern\u00f8","year":"2006","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.phrs.2015.07.023_bib0195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11010-006-9160-4","article-title":"SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects","volume":"289","author":"Raeder","year":"2006","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.phrs.2015.07.023_bib0200","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2007.05.007","article-title":"Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells","volume":"56","author":"Yang","year":"2007","journal-title":"Pharmacol. Res.: Off. J. Italian Pharmacol. Soc."},{"issue":"Suppl. 18","key":"10.1016\/j.phrs.2015.07.023_bib0205","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study","volume":"65","author":"McQuade","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2015.07.023_bib0210","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.2337\/db12-1748","article-title":"Adaptive changes of the Insig1\/SREBP1\/SCD1 set point help adipose tissue to cope with increased storage demands of obesity","volume":"62","author":"Carobbio","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2015.07.023_bib0215","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1172\/JCI26991","article-title":"Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance","volume":"116","author":"Gutierrez-Juarez","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2015.07.023_bib0220","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.neuropharm.2011.08.048","article-title":"Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation?","volume":"62","author":"Lauressergues","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2015.07.023_bib0225","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.schres.2011.03.016","article-title":"Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity","volume":"129","author":"McNamara","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.phrs.2015.07.023_bib0230","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1017\/S1461145708008468","article-title":"Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients","volume":"11","author":"Vik-Mo","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0235","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0306-4530(92)90022-Y","article-title":"Abnormal growth hormone and cortisol, but not thyroid-stimulating hormone, responses to an intravenous glucose tolerance test in normal-weight, bulimic women","volume":"17","author":"Coiro","year":"1992","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2015.07.023_bib0240","first-page":"1082","article-title":"Characterization of the Drosophila lipid droplet subproteome","author":"Beller","year":"2015","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.phrs.2015.07.023_bib0245","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1146\/annurev-biochem-061009-102430","article-title":"Lipid droplets and cellular lipid metabolism","volume":"81","author":"Walther","year":"2012","journal-title":"Ann. Rev. Biochem."},{"key":"10.1016\/j.phrs.2015.07.023_bib0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","article-title":"Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver","volume":"203","author":"Fern\u00f8","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.phrs.2015.07.023_bib0255","doi-asserted-by":"crossref","first-page":"E607","DOI":"10.1152\/ajpendo.00263.2010","article-title":"Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARalpha and FGF21 transcripts in vivo","volume":"299","author":"Berglund","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2015.07.023_bib0260","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cmet.2011.03.009","article-title":"AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice","volume":"13","author":"Li","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2015.07.023_bib0265","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.bcp.2013.02.007","article-title":"Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway","volume":"85","author":"Quan","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0270","doi-asserted-by":"crossref","first-page":"29060","DOI":"10.1074\/jbc.M503824200","article-title":"The Ca2+\/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases","volume":"280","author":"Hurley","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2015.07.023_bib0275","unstructured":"Cruz S. Histamine H3 Receptor Antibody (D-5): sc-390140. http:\/\/wwwscbtcom\/datasheet-390140-histamine-h3-receptor-d-5-antibodyhtml."},{"key":"10.1016\/j.phrs.2015.07.023_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/mol.59.1.1","article-title":"Identification of rat H3 receptor isoforms with different brain expression and signaling properties","volume":"59","author":"Drutel","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0285","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.lfs.2003.06.003","article-title":"Genetic and pharmacological aspects of histamine H3 receptor heterogeneity","volume":"73","author":"Hancock","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2015.07.023_bib0290","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd1631","article-title":"The histamine H3 receptor: from gene cloning to H3 receptor drugs","volume":"4","author":"Leurs","year":"2005","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.phrs.2015.07.023_bib0295","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1476-5381.2011.01285.x","article-title":"Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H(1) and H(3) receptors","volume":"164","author":"Slack","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0300","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0168-8278(03)00353-2","article-title":"Increased concentrations of histamine and its metabolite, tele-methylhistamine and down-regulation of histamine H3 receptor sites in autopsied brain tissue from cirrhotic patients who died in hepatic coma","volume":"39","author":"Lozeva","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0305","doi-asserted-by":"crossref","first-page":"e96147","DOI":"10.1371\/journal.pone.0096147","article-title":"Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1alpha in db\/db mice","volume":"9","author":"Hong","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2015.07.023_bib0310","first-page":"E1107","article-title":"AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle","volume":"273","author":"Merrill","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0315","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","article-title":"Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague\u2013Dawley rats","volume":"217","author":"Weston-Green","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2015.07.023_bib0320","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.lfs.2007.08.009","article-title":"Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats","volume":"81","author":"Choi","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2015.07.023_bib0325","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats","volume":"16","author":"Goudie","year":"2002","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0330","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S146114571300093X","article-title":"Modelling olanzapine-induced weight gain in rats","volume":"17","author":"van der Zwaal","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2015.07.023_bib0335","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.schres.2009.09.034","article-title":"Sensitivity of the female rat to olanzapine-induced weight gain-Far from the clinic","volume":"116","author":"Weston-Green","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.phrs.2015.07.023_bib0340","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/schbul\/sbn023","article-title":"Secondary effects of antipsychotics: women at greater risk than men","volume":"35","author":"Seeman","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2015.07.023_bib0345","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.phrs.2015.07.023_bib0350","first-page":"199","article-title":"Weight gain risk factor assessment checklist: overview and recommendation for use","volume":"32","author":"Treuer","year":"2011","journal-title":"Neuroendocrinol. Lett."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815001565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815001565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T18:58:27Z","timestamp":1567018707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661815001565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":70,"alternative-id":["S1043661815001565"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2015.07.023","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPK\u03b1-SREBP-1 and PPAR\u03b1-dependent pathways","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2015.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}